Pfizer’s RSV vaccine shows benefit in immunosuppressed adults
Pfizer said its respiratory syncytial virus (RSV) vaccine, Abrysvo, generated a strong immune response in a late-stage study of four groups of adults aged 18 years and older with a compromised immune system.
ENTRADAS POPULARES
Poland prepares for peaking floods
septiembre 20, 2024
Italy evacuates thousands as Boris hits the north
septiembre 20, 2024
China and the US race to tame nuclear fusion for clean energy
septiembre 20, 2024
TRANSMISIÓN EN VIVO